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Abstract
Background: SLC11A1 has pleiotropic effects on macrophage function and remains a strong candidate for
infectious disease susceptibility. 5’ and/or 3’ polymorphisms have been associated with tuberculosis, leprosy, and
visceral leishmaniasis (VL). Most studies undertaken to date were under-powered, and none has been replicated
within a population. Association with tuberculosis has replicated variably across populations. Here we investigate
SLC11A1 and VL in India.
Methods: Nine polymorphisms (rs34448891, rs7573065, rs2276631, rs3731865, rs17221959, rs2279015, rs17235409,
rs17235416, rs17229009) that tag linkage disequilibrium blocks across SLC11A1 were genotyped in primary family-
based (313 cases; 176 families) and replication (941 cases; 992 controls) samples. Family- and population-based
analyses were performed to look for association between SLC11A1 variants and VL. Quantitative RT/PCR was used
to compare SLC11A1 expression in mRNA from paired splenic aspirates taken before and after treatment from 24
VL patients carrying different genotypes at the functional promoter GTn polymorphism (rs34448891).
Results: No associations were observed between VL and polymorphisms at SLC11A1 that were either robust to
correction for multiple testing or replicated across primary and replication samples. No differences in expression of
SLC11A1 were observed when comparing pre- and post-treatment samples, or between individuals carrying
different genotypes at the GTn repeat.
Conclusions: This is the first well-powered study of SLC11A1 as a candidate for VL, which we conclude does not
have a major role in regulating VL susceptibility in India.
Keywords: SLC11A1, visceral leishmaniasis, genetic susceptibility
Background
Visceral leishmaniasis (VL) is a debilitating vector borne
disease caused by parasites of the Leishmania donovani
complex. Prevalence is high in Bihar State in India, indi-
cating a need to understand more about disease patho-
genesis to facilitate disease control. Population based
epidemiological surveys suggest that 80-90% of indivi-
duals infected with L. donovani show no clinical symp-
toms [1,2]. Familial clustering, and the range of clinical
outcomes from asymptomatic to fatal disease within and
between ethnic groups sharing similar risk factors in
Brazil [3,4] and Sudan [5,6], support a contribution of
host genotype to susceptibility. Candidate gene and gen-
ome-wide linkage studies have highlighted a number of
genes/gene regions contributing to disease susceptibility
(reviewed [7]). However, replication between study sites
has not been observed possibly due to small samples
size and limited statistical power.
Amongst the genes studied to date, the most compelling
candidate for VL susceptibility is SLC11A1 (formerly
NRAMP1). SLC11A1 encodes solute carrier family 11a
member 1, a transporter that regulates divalent cation
homeostasis in macrophages and has many pleiotropic
effects on macrophage activation (reviewed [8,9]). The
gene was first identified for its role in controlling
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Leishmania donovani (gene designation Lsh), Salmonella
typhimurium (Ity) and Mycobacterium bovis (Bcg) infec-
tions in mice [8,9]. The positionally cloned [10] candidate
for these 3 genes was designated as the natural resistance
associated macrophage protein 1 (Nramp1) for a period
before its specific function as a transporter was confirmed
[11]. In mice, susceptibility to infection is associated with
a coding region mutation in transmembrane domain 4 of
Slc11a1 [10]. In humans, no functional coding region var-
iants have been identified [12], but common alleles 2 [T
(GT)5AC(GT)5AC(GT)10] and 3 [T(GT)5AC(GT)5AC(GT)
9] of a functional [13] Z-DNA forming GTn repeat
(rs34448891) in the promoter region have been associated
with disease risk, or protection from, a number of autoim-
mune and infectious diseases (reviewed [8,14]). Amongst
these associations, a common theme was risk of autoim-
mune disease with allele 3 which drives higher SLC11A1
expression and pro-inflammatory cytokine production by
macrophages, while the lower expressing allele 2 was asso-
ciated with anti-inflammatory cytokines and infectious dis-
ease susceptibility, including tuberculosis [15]. In contrast,
in Sudan the proinflammatory GTn repeat allele 3 is on a
risk haplotype for VL caused by L. donovani that includes
variants at single nucleotide polymorphisms (SNPs) desig-
nated 274C/T in exon 3 (rs2276631) and 469 + 14G/C in
intron 4 (rs3731865) in the 5’ region of the gene [12]. This
was interpreted in relation to VL pathology which is asso-
ciated with a strong pro-inflammatory tumour necrosis
factor alpha response [16]. In some populations infectious
disease association (listed in additional on-line tables in
reference [17]) has been with 3’ variants at SLC11A1
rather than, or in addition to, the 5’ polymorphic loci,
including two insertion/deletion (IN/DEL) polymorphisms
TGTG/- (rs17235416) and CAAA/- (rs17229009) in the
3’UTR. The latter are potentially regulatory polymorph-
isms, although this has not been demonstrated experimen-
tally. Here we report on well-powered two-stage primary
family-based, followed by a replication population-based,
genetic association study that fails to support either a role
for polymorphism at SLC11A1 in determining susceptibil-
ity to VL caused by L. donovani in India, or for the GTn
repeat polymorphism in determining mRNA expression
levels of SLC11A1 in splenic aspirates from VL patients
before or after chemotherapy.
Methods
The study was conducted in the district of Muzaffarpur in
Bihar State, India, where VL is highly endemic. VL cases
and family members or controls were from villages located
within a radius of ~100 km from the city of Muzaffarpur
covering the districts of Muzaffarpur, Vaishali, Samastipur,
Saran, Sheohar, East Champaran and Sitamarhi. Initially,
families with at least two siblings affected with clinical VL
were ascertained from medical records held in the Kala-
Azar Medical Research Centre (KAMRC) in Muzaffarpur,
India [18]. This was later extended to collection of single-
ton cases plus parent (trios) (see Table 1A). The replica-
tion study comprised 958 unrelated cases and 1015
unrelated controls. The controls had no history of VL, or
a family history of VL among first-, second- or third-
degree relatives. Patients and controls were matched for
self-reported age, sex, religion, caste and geographic dis-
trict of recruitment (see Table 1B). Diagnosis of VL was
based on presence of typical clinical features of VL i.e.
fever with rigors and chills, splenomegaly, weight loss and
pancytopenia followed by demonstration of parasites by
parasitological methods (light microscopy, in vitro culture)
using splenic aspirates [19]. Additional VL cases identified
in the field were confirmed on the basis of proof of medi-
cal records of diagnosis and treatment issued from one of
the local health clinics or private practice, and
Table 1 Baseline characteristics of (A) families for the
primary sample of Indian multicase VL families, and (B)
the Indian case-control cohorts
(A) Family Structure Number*
N° families 137
N° nuclear families 176
Nuclear families with 1 affected sib 63
Nuclear families with 2 affected sibs 95
Nuclear families with 3 affected sibs 14
Nuclear families with 4 affected sibs 2
Nuclear families with 5 affected sibs 2
N° affected offspring 313
N° affected parents 63
Total N° affected individuals 394
Total N° individuals 836
(B) Case-Control Sample Number
Cases (no.) 958
Male 571
Female 387
Mean age at study encounter ±SD (yr) 31.2 ±16.7
Range 3-73
Mean age at onset of VL ±SD (yr) 26.8 ±15.3
Religious Group (no.)
Hindu 850
Muslim 108
Controls (no.) 1015
Male 570
Female 445
Mean age at study encounter ±SD (yr) 31.8 ±15.9
Religious Group (no.)
Hindu 885
Muslim 130
* Numbers are given for the individuals with DNA available for genotyping
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accompanied by demonstration of clinical response to
anti-leishmanial treatment (typically with amphotericin B).
An annual incidence rate of 2.49 clinical VL cases/1,000
persons has been reported in the region [20]. L. donovani
sensu strictu (zymodeme MON-2) was confirmed as the
causative agent of VL in the study region, in accordance
with other reports on clinical isolates from kala-azar
patients in the state of Bihar [21-24]. Additional epidemio-
logical and demographic details relating to the study site
are described elsewhere [25]. Informed written consent in
Hindi was obtained from all participating individuals and
from parents of children under 18 years old. Approval for
the study was provided by the Ethical Committee of the
Institute of Medical Sciences, Banaras Hindu University,
Varanasi, India. Collection of families for the primary
study was undertaken between 2004 and 2006. The repli-
cation study collection was undertaken during 2009-2010.
For the family-based primary study DNA was prepared
from buccal swabs by whole genome amplification as
described [18], and SNPs genotyped using ABI prede-
signed Taqman assays (ABI, Mulgrave, Victoria, Australia).
For the replication case-control study, genomic DNA was
extracted from saliva using the Oragene technology (DNA
Genotek, Ontario, Canada), and SNPs genotyped using
Sequenom iPLEX platform (Sequenom, San Diego, CA).
The GTn repeat and IN/DELS were genotyped for all sam-
ples using ABI fragment analysis processed on an
ABI3130 (Australia) or ABI3730 (India) Genetic Analyser.
Family-based allelic association tests based on the
TDT but generalized to allow analysis under additive
and genotype-wise models of inheritance were per-
formed within FBAT under the null hypothesis of “no
linkage and no association” [26,27]. TDT power approx-
imations [28] show that the 313 primary VL trios had
≥95% power to detect an odds ratio ≥2 at P = 0.01 for
markers with MAF ≥ 0.1, but only 49% power for an
odds ratio of 1.5. Nevertheless, our primary sample was
well-powered to detect effect sizes (odds ratios ≥ 2)
equivalent to those observed in the earlier study of
SLC11A1 and VL in Sudan [12]. Robust association tests
were performed to take account of multiple trios within
a pedigree. Association tests for the replication case-
control sample were undertaken using logistic regression
analysis performed in PLINK [29] or LOGIT (Stata)
using an additive model and a genotypic test. The 941
cases and 992 controls which passed quality control
(Hardy-Weinberg Equilibrium) had 100% power to
detect associations with an odds ratio of 2 for markers
with MAF ≥ 0.1 at P = 0.001, and 93.5% power for odds
ratio 1.5; MAF ≥ 0.1, P = 0.01.
Splenic biopsies were taken as part of routine diagnos-
tic procedure at the Kala Azar Medical Research Centre,
Muzaffarpur, Bihar State, India. Since the spleen is a
major focus for parasite growth inside macrophages, this
afforded an important opportunity to analyse gene
expression in a primary site of infection. Pre- and post-
treated patient’s splenic samples were collected in 5 ×
RNA Later (Ambion) during 2009-2010, transported to
Varanasi at 4°C and stored at -80°C until RNA was iso-
lated. Details regarding age and sex (15 males, median
age 16, range 7 to 45 years; 9 females, median age 10,
range 8 to 30 years) splenic parasites (21 confirmed posi-
tive; 3 not done) and drug administered (19 Miltefosine;
1 Miltefosine + Paramomycin; 1Ambisome + Paramomy-
cin; 3Amphomul) were recorded for each patient. Total
RNA was isolated using RNeasy tissue kit (Qiagen)
according to the manufacturer’s instructions and eluted
in 30 ul of RNase free water. Sample quality and integrity
was assessed by ND-2000 spectrophotometer (Thermo
Fischer Scientific) and agarose (Sigma Aldrich) gel elec-
trophoresis. 500 ng of RNA was reverse transcribed using
the High Capacity cDNA synthesis kit (Applied Biosys-
tems). Taqman predesigned gene expression assay
(Hs00184453_m1) was used to perform expression stu-
dies (7500 HT Real Time PCR system, ABI, Foster City
CA, USA) with 18S rRNA (P/N 4319413E) used as an
endogenous control to normalize the expression data.
Experiments were performed on 24 paired pre- and post-
treatment splenic aspirates from VL patients with appro-
priate no RT and no template controls included in each
plate. All samples were run in duplicate. Results were
analysed by 7500 software v.2.0.1 and Graph pad prism 5.
Paired Student’s T tests was used to test for significant
differences between pre (Day-0) and post (D-30) expres-
sion levels for each genotype, i.e. 3/3, 3/2 and 2/2. One
way ANOVA was used to test for differences between 3/
3 vs 3/2 vs 2/2 groups at either Day-0 or Day-30.
Results and Discussion
To undertake our study we initially genotyped 9 poly-
morphisms (Table 2) in 176 nuclear families (Table 1)
used in our previous study [18] that contain 313 offspring
with VL collected in the area of Muzaffarpur, Bihar State,
India, where L. donovani is endemic. This included the
putative functional 5’ GTn repeat and 3’UTR TGTG/-
and CAAA/- IN/DELs, as well as the exon 3 274C/T
(rs2276631) and intron 4 469 + 14G/C (rs3731865) SNPs
shown to be associated with VL in Sudan [12]. Using the
family-based association test (FBAT) [30,31] in this pri-
mary family dataset (Table 3) we found tentative evi-
dence (nominal P-values ≤0.05) for associations between
VL and 5’ GTn repeat, and between VL and the 3’UTR
CAAA/- IN/DEL. In particular (Table 3B), homozygosity
for the high expressing pro-inflammatory allele 3 at the
GTn repeat was associated with disease (Z-score =
+2.382; nominal P = 0.017), while homozygosity for allele
2 (the deletion) was associated with protection for the
3’UTR CAAA IN/DEL (Z-score = -2.332; nominal P =
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0.019). Since these two markers are not in strong LD
with each other (Additional Figure 1: D’ = 0.52; r2 =
0.16), these associations are likely to be independent, if
real. Neither association is robust to application of a
strict Bonferroni correction for 9 SNPs genotyped, which
requires a significance cut-off of P ≤ 0.006 (i.e. P = 0.05/
9). Given that the 8 SNPs that passed quality control are
not all independent (Additional Figure 1), this is over-
conservative. A less stringent correction taking account
of non-independence of markers provides a cut-off of P ≤
0.017 (i.e. P = 0.05/3; 2 LD blocks plus 1 independent
marker).
Table 2 Details of polymorphisms genotyped and the minor allele frequency (MAF) of variants in the Indian study
population
Common Designation Location Amino Acid Change SNP Identity Physical Position1 (bp) Alleles2 MAF
GTn 5’UTR rs34448891 218954900 118/1204 0.190
-237C/T 5’UTR rs7573065 218954951 C/T 0.068
274C/T3 Exon 3 F66F rs2276631 218957257 G/A 0.141
469 + 14G/C3 Intron 4 rs3731865 218958247 C/G 0.142
823 C/T3 Exon 8 G249G rs17221959 218960874 C/T 0.193
1465-85G/A3 Intron 13 rs2279015 218967514 C/T 0.323
D543N G/A3 Exon 15 D543N rs17235409 218967976 G/A 0.073
1729 + 55del43 (TGTG) 3’UTR rs17235416 218968058 IN/DEL 0.067
1729 + 263del43 (CAAA) 3’UTR rs17229009 218968275 DEL/IN 0.287
1 Physical positions of markers are given according to Build 36.3 of the human genome; 2Major > minor alleles for this Indian population; 3bp positions of
variants relative to an arbitrary site 76bp upstream [33] of the methionine start codon; 4allele 3/allele 2 (alleles 1 and 4 were rare or absent from this population).
Table 3 Family-based association analysis between SLC11A1 and VL
(A) Additive model
Common Designation Allele Allele frequency # Fam S E(S) Var(S) Z P
GTn 2 0.15 68 60 70.38 28.4 -1.947 0.052
3 0.85 68 176 165.62 28.4 1.947 0.052
274C/T 1 0.88 43 104 99.65 16.3 1.076 0.282
2 0.12 43 36 40.35 16.3 -1.076 0.282
469 + 14G/C 1 0.11 20 17 21.50 9.7 -1.445 0.148
2 0.89 20 61 56.50 9.7 1.445 0.148
823 C/T 1 0.92 46 127 121.97 20 1.127 0.260
2 0.08 46 41 46.03 20 -1.127 0.260
1465-85G/A 1 0.31 92 117 119.63 42.9 -0.402 0.688
2 0.69 92 229 226.37 42.9 0.402 0.688
1729 + 55del4 (TGTG) 1 0.05 19 18 21.50 9.57 -1.131 0.258
2 0.95 19 54 50.50 9.57 1.131 0.258
1729 + 263del4 (CAAA) 1 0.74 88 216 203.33 41.2 1.974 0.048
2 0.26 88 104 116.67 41.2 -1.974 0.048
(B) Genotype-wise model
Common Designation Genotype Genotype frequency # Fam S E(S) Var(S) Z P
GTn 2\2 0.025 9 8 6.69 2.9 0.759 0.447
2\3 0.250 68 44 57.00 25.7 -2.565 0.010
3\3 0.725 65 66 54.31 24.1 2.382 0.017
1729 + 263del4 (CAAA) 1\1 0.566 75 69 63.57 27.9 1.027 0.304
1\2 0.347 87 78 76.19 33.9 0.311 0.755
2\2 0.087 26 13 20.24 9.64 -2.332 0.019
FBAT analysis under (A) additive and (B) genotype-wise models of inheritance for associations between SLC11A1 polymorphisms and the primary family-based
sample of VL from Bihar State, India. # Fam = number of families informative for the FBAT analysis; S and E(S) represent the observed and expected
transmissions for that allele, Var(S) is the variance. A positive Z score indicates association with disease; a negative Z score indicates the non-associated or
protective allele or genotype. Bold indicates significant associations at nominal P ≤ 0.05. The corrected P-value required to achieve significance taking account of
multiple but not independent markers is P ≤ 0.017. Results are shown for the 7 polymorphisms that were genotyped in the primary family-based sample. All
passed HWE (P-value cut-off 0.05/7 = 0.07 for 7 markers genotyped) in unaffected family founders.
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Suggestive evidence for an association between Indian
VL and allele 3 at the functional promoter region GTn
polymorphism at SLC11A1, which was consistent with
data for VL from Sudan [12], prompted us to pursue two
further avenues of investigation. First, we looked at expres-
sion levels of SLC11A1 in mRNA from splenic aspirates
from patients carrying the 3 different genotypes at the
GTn repeat (Figure 1). This failed to show any significant
differences in expression levels of SLC11A1 in splenic
aspirates from VL patients carrying the three GTn geno-
types, either before or after treatment, as determined
using one way ANOVA. Nor were there differences in
expression within each genotype when pre- and post-treat-
ment values were compared using paired Student’s T tests.
This suggests that differences in expression levels driven
by the GTn repeat in luciferase assays in vitro, especially
under lipopolysaccharide and interferon-g stimulation
[13,32], do not necessarily translate into regulation of
expression in VL infected spleens in vivo. Secondly, we
carried out a comprehensive replication of the association
study in a much larger population-based case-control sam-
ple from the same region of Bihar State in India (Table 4).
Figure 1 Relative expression of SLC11A1 mRNA in splenic aspirates from VL patients (A) before (Day 0), and (B) after (Day 30),
antileishmanial treatment. Data are shown according to genotype (3/3, 2/3, 2/2) at the SLC11A1 GTn promoter repeat polymorphism. Values
represent mean ± SEM. Paired Student’s T test showed no significant differences in expression of SLC11A1 when D0 values were compared to
D30 valules for each genotype. No differences between genotypes were observed at either D0 or D30 as deteremined by one way ANOVA.
Table 4 Population-based association analysis between SLC11A1 and VL
(A) Logistic regression test under additive model
Common Designation Allele Affected Unaffected OR L95 U95 P
GTn 2 355/1473 353/1533 1.05 0.89 1.23 0.585
-237C/T 2 135/1747 122/1862 1.18 0.91 1.52 0.205
274C/T 2 258/1624 286/1698 1.06 0.88 1.27 0.529
469 + 14G/C 1 266/1582 274/1632 1.00 0.83 1.19 0.987
1465-85G/A 1 605/1263 646/1308 1.03 0.90 1.18 0.664
D543N G/A 2 145/1735 112/1526 0.88 0.68 1.14 0.313
1729 + 55del4 (TGTG) 1 110/1488 112/1608 1.06 0.81 1.39 0.669
1729 + 263del4 (CAAA) 2 437/1123 515/1233 0.93 0.80 1.08 0.364
(B) Genotypic-wise logistic regression analysis (2df)
Common Designation Genotypes Cases Controls OR P
GTn 2/2 40 27 1 -
2/3 275 299 0.62 0.070
3/3 599 617 0.66 0.098
1729 + 263del4 (CAAA) 2/2 67 79 1 -
1/2 303 357 0.91 0.346
1/1 410 438 0.90 0.583
Logistic regression analyses under (A) an additive model and (B) using a genotypic (2 df) test for the replication sample of VL cases and controls from Bihar
State, India OR = odds ratio (for minor allele relative to major allele in part A); L95 and U95 are lower and upper 95% confidence intervals. In (A) allele counts are
shown for mino/major allele for affected and unaffected individuals. There were no significant associations at nominal P ≤ 0.05. The corrected P-value required to
achieve significance taking account of multiple but not independent markers is P ≤ 0.017. Data are shown for all markers that were in HWE (P-value cut-off 0.05/
9 = 0.006 for 9 markers genotyped) in the control sample. Marker 823C/T failed HWE quality control. Markers D543N G/A (0.1% cases versus 17% controls) and
1729 + 263del4 (CAAA) (17% cases versus 10.7% controls) showed differential missingness between cases and controls, which can be a concern for its potential
to generate false positive results [34].
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This study failed to show association between VL and any
of the 8 markers that passed quality control. The trend for
genotypic association at the GTn was in the reverse direc-
tion (i.e. a3 was the risk allele in the primary sample, and
the protective allele in the replication samples) to that
seen in the primary analysis (Table 3). Analyses using
caste, which we have shown to provide a good surrogate
for population substructure in genome-wide analyses
(unpublished data), or religion as covariates also failed to
provide evidence for positive associations in the case-con-
trol analysis (data not shown).
Here we re-examined SLC11A1 as a candidate gene for
susceptibility to VL in India. Despite preliminary evidence
for a role for putative functional polymorphisms in the 5’
promoter and 3’UTR regions, we were unable to find sup-
porting evidence for this in functional studies or in a large,
well-powered, replication sample for association analysis.
We conclude that SLC11A1 does not play a major role in
determining susceptibility to VL in India. These results
also call into question the earlier association observed
between VL and SLC11A1 in Sudan [12], which was based
on a single small sample of families. Whilst this could
represent genetic heterogeneity between human popula-
tions and/or the parasite, it is also possible that this first
report of association in humans could be a case of begin-
ner’s curse. Results presented here suggest that associa-
tions observed in small-scale primary samples require
validation to determine whether they remain true for the
population in which they have been observed.
Conclusions
This is the first well-powered study of SLC11A1 as a
candidate for VL, which we conclude does have a major
role in regulating VL susceptibility in India.
Additional material
Additional File 1: Figure S1. Haploview analysis for D’ and r2 pairwise
measures of linkage disequilibrium between SLC11A1 polymorphisms in
the control sample for the replication sample from India.
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